NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Altesa BioSciences

Altesa BioSciences

Private
College Park, GeorgiaHealthcare & Life Scienceshttps://www.altesabio.com/

Last Round

Series B

Feb 19, 2026

Est. Valuation

$190M

Total Funding Raised

$153M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Altesa BioSciences is a biotechnology company that develops antiviral drugs to treat respiratory infections and chronic lung diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antiviral therapeuticsvapendavirrhinovirusbiotechclinical trialsCOPDdrug developmentrespiratory infectionssmall-molecule drugspharma startupclinical-stage biotechdrug discoverybiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Altesa BioSciences Comps

Public and private peers based on sector, stage, and business model.

Altesa BioSciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Altesa BioSciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 19, 2026
Series AJul 1, 2023
Series ADec 22, 2022
SeedFeb 10, 2022
SeedJan 1, 2022

Key People

Founding team and executive leadership

Andy Drechsler

Chief Financial Officer

Executive Team

John Clerici

Chief Operating Officer

Executive Team

Altesa BioSciences Investors

Notable investors and investment history

Altesa BioSciences investors
InvestorRounds
Forbion Capital PartnersSeries B
ForbionSeries B
Georgia Research AllianceSeries A, Seed
Atlantic PartnersSeries B
MedicxiSeries B, Series A
Pitango Venture CapitalSeries B, Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 19, 2026

    $75M round completed.

  • Sep 16, 2025

    Partnered with BioMérieux for Phase IIb trial of vapendavir.

Altesa BioSciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Altesa BioSciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Altesa BioSciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersCollege Park, Georgia
Employee Range20
Year Founded2020
Last FundingFeb 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.